The tool analyzes H&E slides to identify likely presence of 123 biomarkers across 16 cancer types when tissue samples are limited.
Tempus AI has launched Paige Predict, a digital pathology application suite that uses artificial intelligence (AI) to analyze hematoxylin and eosin (H&E) whole slide images and predict biomarker presence when tissue samples are insufficient for full molecular profiling.
The launch represents continued collaboration between Tempus and Paige following Tempus’ acquisition of Paige last year.
The AI-powered solution is designed to help physicians make testing decisions by predicting the likely presence or absence of clinically actionable biomarkers directly from a single H&E slide. When samples are quantity not sufficient, patients can face delays of days or weeks for testing results while waiting for repeat biopsies or alternative testing.
Paige Predict analyzes H&E images to predict the likelihood of 123 biomarkers and oncogenic molecular pathways across 16 cancer types, including non-small cell lung cancer, prostate, breast, pancreatic, and colorectal cancers. Results are automatically delivered with the clinical report to ordering physicians.
The platform can be used by clinicians to inform the sequence in which they order confirmatory tissue-based tests, maximizing the likelihood of receiving an actionable result before exhausting tissue samples.
Built on Large Patient Dataset
Paige Predict was developed using Paige’s foundation model and a combined, multimodal cohort from Tempus and Paige containing de-identified data on more than 200,000 patients. The model has been validated across multiple datasets, including a large-scale cohort from Tempus, according to the company.
“Tissue can be scarce, but insights don’t have to be,” says Ezra Cohen, MD, chief medical officer of oncology at Tempus, in a release. “Paige Predict overcomes one of the biggest barriers in NGS by delivering actionable information to inform critical testing decisions for patient care when sequencing isn’t feasible.”
The solution leverages Tempus and Paige’s digital pathology platform and proprietary AI products to identify critical biomarker information that can guide treatment decisions even when traditional molecular profiling methods are not feasible due to sample limitations.
ID 126299912 | Artificial Intelligence Prediction © Andrey Popov | Dreamstime.com
